Pharmaterials acquired by Quotient Sciences

CDMO Pharmaterials, which offers a wide range of development and manufacturing services for inhaled drugs, has been acquired by Quotient Sciences, Quotient said. Pharmaterials was previously owned by PII, which acquired the company in 2008.

In 2014, Pharmaterials announced that it was adding a dedicated inhalation development laboratory as part of an expansion of its facility in Reading, UK.

Quotient CEO Mark Egerton commented, “The acquisition of Pharmaterials strengthens Quotient’s service portfolio from preclinical formulation development through to commercial manufacturing. The addition expands Quotient’s global CDMO services with added capacity and capabilities to better serve our clients’ needs.”

Read the Quotient Sciences press release.